 |
 |
Ricky |
Interview Transcript
 |
"I like soccer and gardening; it's just fun to do, and I actually get some exercise."
Rebekah (Ricky's Mother):
"When I was 33 weeks pregnant, Ricky pretty much stopped moving in utero. And they, the doctors, told me they could see in the ultrasound he had some kind of fluid in his abdomen that wasn't supposed to be there. By the time he was a couple of weeks old, we knew that he had CF, which was a big shock because I was just 22, a first-time mom. So we found that out and just learned everything we could about it.
He was five years old when he started Pulmozyme. The first thing I noticed with Pulmozyme is he started bringing up more mucus, which was just remarkable; we knew that that was what we needed.
When we first found out that he had it, we just had all these fears of him growing up in a hospital. But it's not like that anymore. He's able to be a kid, and that's really, really important to me."
Product Indication Daily administration of Pulmozyme® (dornase alfa) in conjunction with standard therapies is indicated in the management of cystic fibrosis patients to improve pulmonary function.
Important Safety Information Pulmozyme should not be used in patients who are allergic to any of its ingredients. Pulmozyme should be used along with standard therapies for cystic fibrosis. When starting Pulmozyme therapy, patients may experience change in or loss of their voice, discomfort in the throat, chest pain, red watery eyes, rash, dizziness, fever, or runny nose. These side effects are usually mild and short-lived.
There is a limited amount of information available concerning the usage of Pulmozyme in patients who are younger than 5 years. The decision to use Pulmozyme in these patients is made after considering the potential for a benefit in lung function or in decreasing the risk of respiratory tract exacerbations.
The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to <5 years (younger group) and 33 aged 5 years to ≤10 years (older group). The PARI BABY™ reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. There were more reports of cough, moderate to severe cough, runny nose, and rash in the younger group of patients. Other reported events tended to be of mild to moderate severity. The kind of side effects reported was similar to that of Pulmozyme when used in the larger trials that studied older patients.
Please see the full Product Information for additional safety information.
Individual results may vary.